Zebaze Roger, Zhang Simon, Shore-Lorenti Cat, Chiang Cherie, Milat Frances, Ebeling Peter
Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
Department of Endocrinology, Monash Health, Clayton, Victoria, Australia.
Case Rep Endocrinol. 2025 Jul 13;2025:5583096. doi: 10.1155/crie/5583096. eCollection 2025.
Hypophosphatasia (HPP) is a rare genetic disorder characterized by bone fragility due to defective bone mineralization resulting in impaired alignment of bone components (bone disorganization). Current challenges in the management of HPP include accurately quantifying bone disease severity, monitoring disease progression, and assessing treatment response, particularly in pseudo-fracture healing. Conventional tools such as bone mineral density (BMD) and architecture assessments do not adequately address these issues as they do not assess bone disorganization, limiting their utility in HPP. In this study, we use the ALIGNOGRAM software to reanalyze pseudo-fracture healing in a previously presented case report of an 18-year-old female with benign HPP treated with asfotase alfa. We show that improvements in bone disorganization were detectable as early as 3 months after treatment initiation-before changes on X-ray or bone scintigraphy were detected. As such, assessment of the degree of bone disorganization could serve as an early indicator of treatment efficacy in HPP.
低磷性骨软化症(HPP)是一种罕见的遗传性疾病,其特征是由于骨矿化缺陷导致骨脆性增加,从而导致骨成分排列受损(骨结构紊乱)。目前HPP管理面临的挑战包括准确量化骨病严重程度、监测疾病进展以及评估治疗反应,尤其是在假性骨折愈合方面。传统工具如骨密度(BMD)和骨结构评估无法充分解决这些问题,因为它们不评估骨结构紊乱,限制了它们在HPP中的效用。在本研究中,我们使用ALIGNOGRAM软件对之前一份关于一名接受阿法骨化醇治疗的18岁良性HPP女性病例报告中的假性骨折愈合情况进行重新分析。我们发现,早在治疗开始后3个月,在X射线或骨闪烁显像检测到变化之前,就可以检测到骨结构紊乱的改善。因此,评估骨结构紊乱程度可以作为HPP治疗效果的早期指标。